indirubin-3'-monoxime has been researched along with Lung Neoplasms in 6 studies
indirubin-3'-monoxime: has antiangiogenic activity
indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For drug combination experiment analysis, response surface modeling has been commonly adopted." | 1.40 | An application of a Hill-based response surface model for a drug combination experiment on lung cancer. ( Al-Shyoukh, I; Feng, J; Ning, S; Sun, R; Xu, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JW | 1 |
| Moon, MJ | 1 |
| Min, HY | 1 |
| Chung, HJ | 1 |
| Park, EJ | 1 |
| Park, HJ | 1 |
| Hong, JY | 1 |
| Kim, YC | 2 |
| Lee, SK | 1 |
| Dera, AA | 1 |
| Rajagopalan, P | 2 |
| Al Fayi, M | 1 |
| Ahmed, I | 1 |
| Chandramoorthy, HC | 1 |
| Dera, A | 1 |
| Abdalsamad, MR | 1 |
| C Chandramoorthy, H | 1 |
| Ning, S | 1 |
| Xu, H | 1 |
| Al-Shyoukh, I | 1 |
| Feng, J | 1 |
| Sun, R | 1 |
| Ahn, MY | 1 |
| Kim, TH | 1 |
| Kwon, SM | 1 |
| Yoon, HE | 1 |
| Kim, HS | 1 |
| Kim, JI | 1 |
| Kang, KW | 1 |
| Ahn, SG | 1 |
| Yoon, JH | 1 |
| Ravichandran, K | 1 |
| Pal, A | 1 |
| Ravichandran, R | 1 |
6 other studies available for indirubin-3'-monoxime and Lung Neoplasms
| Article | Year |
|---|---|
Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinas | 2005 |
Indirubin-3-monoxime and thymoquinone exhibit synergistic efficacy as therapeutic combination in in-vitro and in-vivo models of Lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Cycle; Cell Line; Cell Pr | 2020 |
Rational combinations of indirubin and arylidene derivatives exhibit synergism in human non-small cell lung carcinoma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associ | 2019 |
An application of a Hill-based response surface model for a drug combination experiment on lung cancer.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Butadienes; Cell Line, Tumor | 2014 |
5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tu | 2015 |
Effect of indirubin-3-monoxime against lung cancer as evaluated by histological and transmission electron microscopic studies.
Topics: Animals; Antineoplastic Agents; Benzo(a)pyrene; Cell Count; Cell Nucleus; Cell Proliferation; Cell S | 2010 |